Cardiovascular disease and chronic renal disease: A new paradigm

被引:453
作者
Sarnak, MJ [1 ]
Levey, AS [1 ]
机构
[1] Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA
关键词
cardiovascular disease; chronic renal disease; hemodialysis; peritoneal dialysis; renal transplantation; risk factors;
D O I
10.1016/S0272-6386(00)70239-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) is a major cause of morbidity and mortality among patients with chronic renal disease (CRD). Despite improvement in treatment for CVD over the past 30 years, CVD mortality is approximately 15 times higher in dialysis patients than in the general population. The high prevalence of CVD among incident dialysis patients suggests that CVD begins in earlier stages of CRD, and that implementation of risk factor reduction strategies earlier in the course of CRD may provide an opportunity to prevent CVD in CRD. Based on parallels between CVD and renal disease progression, we have proposed a paradigm that CVD and CRD are outcomes of the same underlying disorders. We propose that risk factor reduction strategies used to prevent CVD in the general population also be applied to patients with CRD, with the hope of preventing progression of renal disease, as well as preventing CVD. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:S117 / S131
页数:15
相关论文
共 76 条
  • [1] NATURAL-HISTORY OF ASYMPTOMATIC CORONARY ARTERIOGRAPHIC LESIONS IN DIABETIC-PATIENTS WITH END-STAGE RENAL-DISEASE
    BENNETT, WM
    KLOSTER, F
    ROSCH, J
    BARRY, J
    PORTER, GA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1978, 65 (05) : 779 - 784
  • [2] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    Besarab, A
    Bolton, WK
    Browne, JK
    Egrie, JC
    Nissenson, AR
    Okamoto, DM
    Schwab, SJ
    Goodkin, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) : 584 - 590
  • [3] Sudden and cardiac death rates in hemodialysis patients
    Bleyer, AJ
    Russell, GB
    Satko, SG
    [J]. KIDNEY INTERNATIONAL, 1999, 55 (04) : 1553 - 1559
  • [4] BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P521
  • [5] BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P184
  • [6] Relationship of dose of hemodialysis and cause-specific mortality
    Bloembergen, WE
    Stannard, DC
    Port, FK
    Wolfe, RA
    Pugh, JA
    Jones, CA
    Greer, JW
    Golper, TA
    Held, PJ
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (02) : 557 - 565
  • [7] High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
    Bostom, AG
    Shemin, D
    Lapane, KL
    Hume, AL
    Yoburn, D
    Nadeau, MR
    Bendich, A
    Selhub, J
    Rosenberg, IH
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (01) : 147 - 152
  • [8] Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study
    Bostom, AG
    Shemin, D
    Verhoef, P
    Nadeau, MR
    Jacques, PF
    Selhub, J
    Dworkin, L
    Rosenberg, IH
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 2554 - 2558
  • [9] Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
    Bostom, AG
    Lathrop, L
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (01) : 10 - 20
  • [10] Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects
    Cannella, G
    Paoletti, E
    Delfino, R
    Peloso, G
    Rolla, D
    Molinari, S
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (05) : 659 - 664